PMID- 34713949
OWN - NLM
STAT- MEDLINE
DCOM- 20220310
LR  - 20220310
IS  - 1440-1797 (Electronic)
IS  - 1320-5358 (Linking)
VI  - 27
IP  - 2
DP  - 2022 Feb
TI  - The efficacy and safety of hydroxychloroquine in pregnant patients with IgA 
      nephropathy: A retrospective cohort study.
PG  - 155-161
LID - 10.1111/nep.13991 [doi]
AB  - AIM: Hydroxychloroquine (HCQ) is used to control proteinuria in IgA Nephropathy 
      (IgAN) However, its efficacy and safety in pregnant IgAN patients remains 
      unknown. This study aimed to verify the safety of HCQ in pregnant IgAN patients 
      and compare renal function and pregnancy outcomes with those of patients not 
      treated with HCQ. METHODS: We retrospectively reviewed medical records of all 
      pregnant IgAN patients and singleton gestations at Peking University First 
      Hospital from 2003-2021. Patients who did and did not receive HCQ treatment 
      during pregnancy were compared. RESULTS: We found no significant pre- or 
      post-pregnancy differences in proteinuria or renal function between the two 
      groups. However, the HCQ (+) group had higher proteinuria at the time of kidney 
      biopsy (2.04 [1.26, 2.56] g/d vs. 0.80 [0.44, 1.11] g/d, P < .001); the 
      proteinuria level at HCQ therapy initiation was also higher than that at the 
      beginning of pregnancy (1.87 [1.30, 2.59] g/d vs. 1.08 [0.75, 1.50] g/d, 
      P = .001). Despite no difference in preterm birth, birth weight, preeclampsia or 
      postpartum haemorrhage, the proportion of patients with a previous history of 
      spontaneous abortion was higher in the HCQ (+) group than in the HCQ (-) group 
      (48.0% vs. 20.6%, P = .010). The eGFR (regression coefficient, 0.981; 95%CI 
      0.964-0.998) was a predictive factor for obstetrical complications. CONCLUSION: 
      HCQ is safe for IgAN treatment during pregnancy with effective reduction of 
      proteinuria. HCQ might also be helpful in patients with a history of spontaneous 
      abortion.
CI  - (c) 2021 Asian Pacific Society of Nephrology.
FAU - Tang, Chen
AU  - Tang C
AUID- ORCID: 0000-0002-7225-9105
AD  - Renal Division, Peking University First Hospital, Peking University Institute of 
      Nephrology, Beijing, China.
AD  - Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of 
      Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of 
      Education, Beijing, China.
AD  - Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, 
      Chinese Academy of Medical Sciences, Beijing, China.
FAU - Si, Feng-Lei
AU  - Si FL
AD  - Renal Division, Peking University First Hospital, Peking University Institute of 
      Nephrology, Beijing, China.
AD  - Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of 
      Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of 
      Education, Beijing, China.
AD  - Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, 
      Chinese Academy of Medical Sciences, Beijing, China.
FAU - Yao, Yu-Xuan
AU  - Yao YX
AD  - Renal Division, Peking University First Hospital, Peking University Institute of 
      Nephrology, Beijing, China.
AD  - Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of 
      Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of 
      Education, Beijing, China.
AD  - Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, 
      Chinese Academy of Medical Sciences, Beijing, China.
FAU - Lv, Ji-Cheng
AU  - Lv JC
AD  - Renal Division, Peking University First Hospital, Peking University Institute of 
      Nephrology, Beijing, China.
AD  - Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of 
      Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of 
      Education, Beijing, China.
AD  - Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, 
      Chinese Academy of Medical Sciences, Beijing, China.
FAU - Shi, Su-Fang
AU  - Shi SF
AD  - Renal Division, Peking University First Hospital, Peking University Institute of 
      Nephrology, Beijing, China.
AD  - Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of 
      Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of 
      Education, Beijing, China.
AD  - Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, 
      Chinese Academy of Medical Sciences, Beijing, China.
FAU - Chen, Yu-Qing
AU  - Chen YQ
AD  - Renal Division, Peking University First Hospital, Peking University Institute of 
      Nephrology, Beijing, China.
AD  - Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of 
      Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of 
      Education, Beijing, China.
AD  - Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, 
      Chinese Academy of Medical Sciences, Beijing, China.
FAU - Liu, Li-Jun
AU  - Liu LJ
AD  - Renal Division, Peking University First Hospital, Peking University Institute of 
      Nephrology, Beijing, China.
AD  - Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of 
      Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of 
      Education, Beijing, China.
AD  - Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, 
      Chinese Academy of Medical Sciences, Beijing, China.
FAU - Zhang, Hong
AU  - Zhang H
AUID- ORCID: 0000-0001-9855-4068
AD  - Renal Division, Peking University First Hospital, Peking University Institute of 
      Nephrology, Beijing, China.
AD  - Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of 
      Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of 
      Education, Beijing, China.
AD  - Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, 
      Chinese Academy of Medical Sciences, Beijing, China.
LA  - eng
GR  - 2019-I2M-5-046/CAMS Innovation Fund for Medical Sciences/
GR  - 82070731/The General Program (Key Program, Major Research Plan) of National 
      Natural Science Foundation of China/
PT  - Journal Article
DEP - 20211110
PL  - Australia
TA  - Nephrology (Carlton)
JT  - Nephrology (Carlton, Vic.)
JID - 9615568
RN  - 4QWG6N8QKH (Hydroxychloroquine)
SB  - IM
MH  - Adult
MH  - Cohort Studies
MH  - Female
MH  - Glomerulonephritis, IGA/*drug therapy/physiopathology
MH  - Humans
MH  - Hydroxychloroquine/adverse effects/*therapeutic use
MH  - Kidney Function Tests
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy
MH  - Pregnancy Outcome
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - IgA nephropathy
OT  - hydroxychloroquine
OT  - pregnancy
OT  - proteinuria
OT  - renal function
EDAT- 2021/10/30 06:00
MHDA- 2022/03/11 06:00
CRDT- 2021/10/29 09:01
PHST- 2021/10/21 00:00 [revised]
PHST- 2021/08/26 00:00 [received]
PHST- 2021/10/21 00:00 [accepted]
PHST- 2021/10/30 06:00 [pubmed]
PHST- 2022/03/11 06:00 [medline]
PHST- 2021/10/29 09:01 [entrez]
AID - 10.1111/nep.13991 [doi]
PST - ppublish
SO  - Nephrology (Carlton). 2022 Feb;27(2):155-161. doi: 10.1111/nep.13991. Epub 2021 
      Nov 10.